-
FEMS Immunology and Medical Microbiology Aug 2010The antibiofilm activity of a glycolipid biosurfactant isolated from the marine actinobacterium Brevibacterium casei MSA19 was evaluated against pathogenic biofilms in...
The antibiofilm activity of a glycolipid biosurfactant isolated from the marine actinobacterium Brevibacterium casei MSA19 was evaluated against pathogenic biofilms in vitro. The isolate B. casei MSA19 was a potential biosurfactant producer among the 57 stable strains isolated from the marine sponge Dendrilla nigra. The biosurfactant production was optimized under submerged fermentation. The purified glycolipid showed a broad spectrum of antimicrobial activity. Based on the minimum inhibitory concentration/minimum bactericidal concentration ratio, the glycolipid was determined as bacteriostatic. The glycolipid biosurfactant disrupted the biofilm formation under dynamic conditions. The disruption of the biofilm by the MSA19 glycolipid was consistent against mixed pathogenic biofilm bacteria. Therefore, the glycolipid biosurfactant can be used as a lead compound for the development of novel antibiofilm agents.
Topics: Alteromonas; Animals; Anti-Infective Agents; Biofilms; Brevibacterium; Candida albicans; Enterobacteriaceae; Glycolipids; Humans; Microbial Sensitivity Tests; Microbial Viability; Porifera; Pseudoalteromonas; Pseudomonas aeruginosa; Rhodobacteraceae; Surface-Active Agents; Vibrio
PubMed: 20528933
DOI: 10.1111/j.1574-695X.2010.00698.x -
Peritoneal Dialysis International :... 2012
Topics: Actinomycetales Infections; Adult; Brevibacterium; Genes, rRNA; Humans; Male; Peritonitis; RNA, Ribosomal, 16S; Recurrence; Sequence Analysis, RNA
PubMed: 22641738
DOI: 10.3747/pdi.2011.00179 -
Journal of Clinical Microbiology Sep 2000Brevibacterium sp. was isolated from the blood of an acutely ill 18-year-old female with AIDS. The isolate was identified as Brevibacterium casei by use of carbohydrate...
Brevibacterium sp. was isolated from the blood of an acutely ill 18-year-old female with AIDS. The isolate was identified as Brevibacterium casei by use of carbohydrate assimilation tests. Treatment was successful with intravenously administered ciprofloxacin. To our knowledge, this is the first report of sepsis caused by B. casei in a human immunodeficiency virus-infected patient.
Topics: AIDS-Related Opportunistic Infections; Adolescent; Bacteremia; Brevibacterium; Female; Gram-Positive Bacterial Infections; Humans
PubMed: 10970420
DOI: 10.1128/JCM.38.9.3513-3514.2000